The Pediatric Hematology/Oncology Fellowship Program at the University of Colorado Denver (UCD) and The Children's Hospital (TCH) has a distinguished history spanning over 35 years. Over the last 5 years, the Training Program has benefited significantly with the transition to the newly built Anschutz Medical Campus (AMC). The Pediatric Oncology laboratories relocated in the 2004-2005 academic year into expanded, state-of-the art research space on the AMC. In September 2007, TCH also relocated onto the AMC into a new 1.44 million square feet hospital that includes 294 beds and serves patients from seven states in the Rocky Mountain region. Thus, for the first time in the history of the program, Pediatric Oncology trainees are located on one medical campus which includes TCH, University of Colorado Hospital, UCD School of Medicine, and the Colorado Biosciences Park. The Pediatric Oncology Fellowship Program and faculty also grew significantly in size during this transition to the new campus and now consist of 25 Clinical Faculty with 4 new fellows entering the 3-year Fellowship Program annually. In parallel, the T32 Research Training Faculty has been expanded to 30 members, increasing the opportunities given to fellows to perform laboratory-based, translational or clinical research in pediatric oncology. The T32 Training Faculty represent a broad range of scientific disciplines including cell cycle control and signaling, transcriptional regulation and splicing, virology, and immunology. Training Faculty with specific expertise in clinical research and translational oncology, including identification of novel biologic targets for drug development, have also been added. The Training Program was initially funded in 2000 with this T32 grant, and the current submission is the second competitive renewal of this support. Because of the breadth of the clinical experience, the outstanding clinical reputation of the Children's Hospital, and the new research opportunities available, fellowship candidates since 1993 have consistently increased in quality and dedication to an academic career. Indeed, 13 of 15 graduates in the last 5 years of the Fellowship Program are now in academic faculty, and all graduates since 2007 have academic faculty positions. The minimal fellowship duration is three years. The first year is devoted almost exclusively to clinical training, while at least 80% of time during years 2 and 3 is devoted to research. Currently there are 12 fellows in the Program, all of whom have previously completed their Pediatric residencies, with 8 currently in research training beyond their first clinical fellowship year. This proposal seeks funding for those MD fellows who elect to pursue research related to Pediatric Oncology in the second and subsequent years of the fellowship, and select PhD post-doctoral fellows committed to a career in pediatric cancer research. Both history and recent developments thus mark this training program as one of the best in the nation.

Public Health Relevance

The University of Colorado Denver has an established history of providing outstanding clinical and research training to Pediatric Hematology/Oncology fellows. Continued funding of this program will help provide future academic leaders skilled in the care of pediatric oncology patients and trained in scientific research necessary to advance knowledge of pediatric cancer, and to develop and test new treatment options.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Schools of Medicine
United States
Zip Code
Minson, Katherine A; Smith, Catherine C; DeRyckere, Deborah et al. (2016) The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight 1:e85630
Hudish, Laura I; Galati, Domenico F; Ravanelli, Andrew M et al. (2016) miR-219 regulates neural progenitors by dampening apical Par protein-dependent Hedgehog signaling. Development 143:2292-304
Gump, Jacob M; Donson, Andrew M; Birks, Diane K et al. (2015) Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathol Commun 3:30
Ford, James B; Baturin, Dmitry; Burleson, Tamara M et al. (2015) AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget 6:28001-10
Ravanelli, Andrew M; Appel, Bruce (2015) Motor neurons and oligodendrocytes arise from distinct cell lineages by progenitor recruitment. Genes Dev 29:2504-15
Blevins, Melanie A; Towers, Christina G; Patrick, Aaron N et al. (2015) The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opin Ther Targets 19:213-25
Hines, Jacob H; Ravanelli, Andrew M; Schwindt, Rani et al. (2015) Neuronal activity biases axon selection for myelination in vivo. Nat Neurosci 18:683-9
Pierce, Angela M; Keating, Amy K (2014) TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system. Brain Res 1542:206-20
Gump, Jacob M; Thorburn, Andrew (2014) Sorting cells for basal and induced autophagic flux by quantitative ratiometric flow cytometry. Autophagy 10:1327-34
Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra et al. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57:7031-41

Showing the most recent 10 out of 76 publications